By Fineline Cube 
Aureka Biotechnologies, a global leader in the Tech-Bio space, announced the completion of a Series B financing round totaling USD 100 million. The round was executed in tranches: the initial tranche was solely invested by Granite Asia, while subsequent tranches were led by prominent industry investors with participation from HighLight Capital (HLC), alongside continued investments from existing shareholders including Qiming Venture Partners, MPCi, and NRL Capital. To date, Aureka Biotechnologies has raised nearly USD 200 million in total funding.
Financing Overview
| Item | Detail |
|---|---|
| Company | Aureka Biotechnologies |
| Round | Series B |
| Size | USD 100 million |
| Structure | Multi‑tranche |
| Initial Tranche | Solely invested by Granite Asia |
| Subsequent Tranches | Led by prominent industry investors, with HighLight Capital (HLC) participating |
| Existing Investors | Qiming Venture Partners, MPCi, NRL Capital |
| Cumulative Funding | Nearly USD 200 million |
| Announcement Date | 11 Aug 2026 |
Company Profile
- Founded: 2023 | Positioning: AI‑native TechBio company
- Core Mission: Dedicated to developing next‑generation biological foundation models.
- Infrastructure: Building an AI‑native, closed‑loop infrastructure integrating AI models, intelligent agents, digital biotechnology, and experimental platforms to reshape the entire drug discovery process.
Use of Proceeds
- Foundation Model R&D: Proceeds will primarily support the R&D and large‑scale training of next‑generation biological foundation models, continuously elevating capabilities in core tasks such as de novo molecular design, biological structure modeling, and functional prediction.
- “Lab‑in‑the‑Loop” Upgrade: The company plans to upgrade its experiment‑centric feedback mechanism, the “Lab‑in‑the‑Loop” system, facilitating deep integration between its foundation models and proprietary single‑cell functional screening, high‑throughput experimental verification, and drug development platforms.
Market Impact & Outlook
- AI‑Bio Funding Momentum: The USD 100 million round adds to a wave of large financings for AI‑native biotech builders, as investors concentrate capital on platforms combining foundation models with proprietary experimental validation.
- Differentiated Architecture: The closed‑loop design — pairing foundation models with a wet‑lab feedback system — addresses a key industry critique of purely computational drug discovery by grounding model outputs in experimental data.
- Investor Conviction: Follow‑on participation from existing backers across tranches signals sustained confidence in the company’s execution since its 2023 founding.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding platform development and use of proceeds. Actual results may differ due to risks including model development progress, experimental validation outcomes, and market conditions.-Fineline Info & Tech